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Structured Abstract 
Purpose: To review the evidence concerning screening for dementia syndrome 
(hereafter, dementia) in primary care settings to support recommendations from the US 
Preventive Services Task Force (USPSTF). 
Data Sources: We searched MEDLINE, PsychiNFO, EMBASE, and the Cochrane 
Collaboration Library from January 1994 to November 2001, with all searches limited to English 
language studies. 
Study Selection: We developed an analytic framework and key questions concerning 
dementia screening and treatment to guide our search. We developed inclusion and exclusion 
criteria for each key question. For questions of prevalence or accuracy of screening tests, we 
required cross-sectional or cohort studies in a primary care population with an acceptable 
reference standard for diagnosis. For questions of treatment, we included randomized controlled 
trials (RCTs) of subjects with mild to moderate dementia. 
Data Extraction: Two reviewers agreed on studies meeting inclusion and exclusion 
criteria and graded them according to USPSTF criteria. They then extracted data from included 
studies of fair to good quality and entered the data into evidence tables. 
Data Synthesis: The prevalence of dementia increases with age and affects 25% to 47% 
of people age 85 years and older. More than one-half of patients with dementia in primary care 
practices are undiagnosed. We found no RCT of screening for dementia. The Mini-Mental 
Status Examination (MMSE) is a brief screening tool with clinically acceptable reliability and 
accuracy. Although no effective treatment has yet been documented for early vascular dementia, 
cholinesterase inhibitors slow the rate of cognitive decline in people with mild to moderate 
Alzheimer's disease with mild adverse effects. Antidepressant medication is effective in 
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reversing depressive symptoms in early dementia, but medical treatment of other behavioral and 
mood symptoms in early dementia is poorly studied. Intensive multi-component interventions 
for caregivers may delay nursing home placement and decrease caregiver burden, but they do not 
affect patients' health outcomes. Other benefits of screening and the potential harm of labeling 
have not been studied. 
Conclusion: Screening tests can detect undiagnosed dementia and cholinesterase 
inhibitors effectively slow the rate of cognitive decline in people with mild to moderate 
Alzheimer's disease. The effect of these drugs or other treatments on people with dementia 
detected by screening is uncertain. 
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Introduction 
Dementia is an acquired syndrome of decline in memory and at least one other cognitive 
domain, such as language, visuo-spatial, or executive function sufficient to interfere with social 
or occupational functioning in an alert person(l ). Multiple diseases can cause the dementia 
syndrome (hereafter, dementia). Alzheimer's disease and cerebrovascular ischemia are the two b 
most common causes. Although such potentially reversible causes as hypothyroidism or vitamin 
Bl2 deficiency are often considered causes of dementia, no more than 1.5% of cases of mild to 
moderate dementia are fully reversible(2). t 
b 
Age is the best studied and the strongest risk factor for dementia. Other risk factors for f I 
I Alzheimer's disease include having a first-degree relative with a history of Alzheimer's disease, the apolipoprotein E-4 genotype, or a previous history of head trauma(3-5). Cardiovascular risk 
factors such as hypertension are associated with an increased risk of both Alzheimer's disease F 
and vascular dementia(3;6;7). 
The aging of the US population has been accompanied by a dramatic rise in the 
prevalence of dementia. From 3% to II% of persons over age 65 and 25% to 47% of those over 
age 85 have dementia(S-13). In 1997, the number of people with Alzheimer's disease in the 
United States was estimated to be 2.3 million, more than 90% of whom were ages 60 years- and 
older(14). 
Dementia causes a high burden of suffering for patients, their families, and 
society(15;16). For patients, it leads to increased dependency and falls, and complicates other 
comorbid conditions. For families, it leads to anxiety, depression, and increased time in caring 
for a loved one. The annual societal cost of dementia is approximately $100 billion, from health 
care and related costs as well as lost wages for patients and family caregivers(10;17). 
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Clinicians using routine history and physical examination do not readily diagnose 
dementia during clinic visits. More than 50% of people with dementia have never been 
diagnosed by a physician(l8-22). This raises the possibility that screening tests might be able to 
identify people with undiagnosed dementia, to permit more patients to receive treatment and to 
deliver treatment at an earlier stage in the disease process. Given the low prevalence of 
reversible causes, a recommendation for screening will depend on evidence of benefits for 
persons with irreversible causes, primarily Alzheimer's disease and vascular dementia. 
For dementia screening to lead to improved health outcomes, primary care providers 
would need to have a brief, accurate screening test to apply during routine office visits. A 
positive screening test would then result in an in-depth diagnostic interview and clinical 
examination performed by either the primary physician or a specialist such as a geriatrician or 
neurologist trained in the diagnosis of dementia. Finally, effective treatment would be available 
for many people diagnosed with dementia that would improve health outcomes. Ideal evidence 
for dementia screening would come from a randomized controlled trial (RCT) of a screening 
intervention with long-term follow-up for both adverse and beneficial effects of screening. 
The 1996 Guide to Clinical Preventive Services from the US Preventive Services Task 
Force (USPSTF) found insufficient evidence to recommend either for or against screening(23). 
Since the last USPSTF review, several studies have been published concerning both 
pharmacologic and caregiver interventions. Given the new evidence and the large and growing 
importance of this condition, the RTI-University ofNorth Carolina Evidence-based Practice 
Center (RTI-UNC EPC) conducted a systematic review of the literature regarding the benefits 
and the harms of screening primary care populations to detect undiagnosed cases of dementia. 
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Methods 
Using USPSTF methods(24), we developed an analytic framework and key questions to 
guide our systematic review of the evidence for dementia screening. We searched first for 
studies of screening that provided direct evidence that screening improves cognitive, social, or 
physical function; number of hospitalizations, institutionalizations, or health care visits; 
behavioral problems; caregiver burden; accidental injury such as falls or automobile crashes; and 
patients' overall health-related quality oflife. We next searched for indirect evidence of the 
benefit of screening, the prevalence of undiagnosed dementia, the accuracy of screening tests, 
and the efficacy of pharmacologic treatment and nonpharmacologic interventions for 
Alzheimer's disease and vascular dementia. We also searched for evidence of the adverse 
effects of screening and treatment. 
We developed inclusion and exclusion criteria for selecting the evidence relevant to 
answer the key questions. Table 1 lists these criteria and the number of articles found meeting 
them for each question. We used the inclusion and exclusion criteria to develop search terms, 
and searched MEDLINE, PsychlNFO, EMBASE, and Cochrane Library databases for systematic 
reviews and high-quality studies relevant to each question. We limited all searches to reviews 
and studies published in the English language between January 1, 1994, and November 5, 2001, 
with information relevant for a primary care population. 
At least 2 authors reviewed abstracts and articles to identify those that met the inclusion 
criteria and then abstracted relevant information using standardized abstraction forms. We 
graded the articles using criteria developed by the USPSTF Methods Work Group(24). The 
authors worked closely with 2 members of the USPSTF throughout the review, periodically 
presenting reports to the full USPSTF. We distributed a draft systematic evidence review for 
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external peer review by experts in the field and relevant professional organizations and federal 
agencies and made revisions based on the feedback. 
A more complete account of the methods of this review is available in the Appendix on 
the Annals of Internal Medicine website(25). The complete evidence review is available on the 
AHRQ website(2). 
Results 
How Common is Undiagnosed Dementia? 
Three studies in primary care populations ages 65 years and older compared the 
frequency of dementia by standard diagnostic tests with medical record notation of dementia or 
cognitive impairment(21;22;26). From 3.2% to 12% of all patients met criteria for dementia but 
had no dementia documentation (Table 2). A population-based study found that the prevalence 
of undiagnosed dementia among individuals ages 65 years and older was 1.8%(27). 
Undiagnosed patients accounted for 50% to 66% of all cases of dementia in the primary 
care populations studied. In one small study, 78.6% (11114) ofpeop1e with mild dementia, 
71.4% (5/7) with moderate dementia, and 20% (1/5) with severe dementia had no medical record 
documentation(22). New screening testing in primary care practice could, therefore, double the 
number of patients diagnosed with dementia, and most newly discovered cases would have mild 
to moderate disease. 
How ):\ccurate are the Screening Tests? 
The most widely used and studied screening test for dementia is the Mini-Mental State 
Examination (MMSE), a 30-point structured examination that can be completed in 5 to 10 
Manuscript for Review Purposes: Do Not Cite, Quote, Reproduce, or Distribute Without Pennission 
February 12, 2002 
b 
L 
. 
L 
E p 
Screening for Dementia 8 
minutes in a clinical encounter(28). The test has reasonable reliability(28;29), but it requires 
reading, writing, and mathematics, and thus must be adjusted for educational status(30-35). 
MMSE scores below 26 have been shown to correlate with development of clinical 
dementia within the next 3 to 6 years; a score of25 has a likelihood ratio (LR) of2.30 and a 
score of24 has a LR of2.45(36). At these cutpoints (i.e., 24 to 26), population-based studies in 
Canada have found the sensitivity of the MMSE to be between 70% and 86% with a specificity 
of77% to 82%(29;37). If the MMSE were used to screen a population with a prevalence of 
undiagnosed dementia of 10%, about one-third of people with a positive screening test would 
actually have dementia on further diagnostic testing. This proportion declines when the MMSE 
is used in groups with a lower prevalence of dementia. 
Several other screening tests have been proposed (the Clock-Drawing Test, the Modified 
Mini-Mental State Examination, the Mini-Cog, and the Instrumental Activities of Daily Living 
[IADL} score), including some that are less dependent than the MMSE on educational status. 
None, however, is as well studied or has been shown to be consistently superior to the MMSE in 
the general population. Testing for genetic mutations is a new approach that requires further 
study. 
How Effective is Treatment for Mild to Moderate Vascular Dementia? 
Although antihypertensive treatment reduces the development of stroke, the evidence is 
limited that similar treatment of people with mild to moderate vascular dementia prevents further 
progression of the dementia(38). One systematic review found no effect of aspirin on cognitive 
symptoms in people with vascular dementia(3 9). 
Manuscript for Review Purposes: Do Not Cite, Quote, Reproduce, or Distribute Without Permission 
February 12, 2002 
fc---
L 
b 
l 
I 
Screening for Dementia 
How Effective are Cholinesterase Inhibitors for People with Mild to Moderate 
Alzheimer's Disease? 
Because autopsy studies found that acetylcholine is depleted in the brains of people with 
Alzheimer's disease, several research teams have studied cholinesterase inhibitors for their 
efficacy in improving cognition and function in these people. The Food and Drug 
Administration has approved 4 cholinesterase inhibitors for use in Alzheimer's disease. 
Thirteen well-conducted RCTs and systematic reviews met our inclusion criteria. They 
examined the effects of cholinesterase inhibitors on people with mild to moderate Alzheimer's 
disease (apparently detected clinically rather than by screening) (Table 3) (40-52). Nearly all 
9 
found a statistically significant difference in cognitive function between drug and placebo groups 
after 6 to 12 months. This difference manifests as a reduced rate of cognitive decline, as 
opposed to an improvement, in people taking cholinesterase inhibitors compared with those 
taking placebo. 
After 6 to 12 months of treatment, the magnitude of the difference between the 
cholinesterase inhibitor and placebo groups is 4% to 6% on cognitive function scales. The usual 
annual decline in cognition on research measurement scales for people with mild to moderate 
Alzheimer's disease is 7% for mild dementia and 10% to 15% for moderate dementia(53;54). In 
addition to its effects on cognition, cholinesterase inhibitors stabilized or slightly improved a 
scale of clinician global impression of change after 6 to 12 months of treatment. 
The evidence is mixed about the effects of cholinesterase inhibitors on functional 
measures such as IADLs. In general, the studies show an uncertain reduction in functional 
decline after 6 months of treatment but a statistically significant difference from placebo after 12 
-months of treatment( 55-59). The difference in function between treatment and placebo groups is 
small, approximately 1% to 3%. The most positive study was a 12-month RCT of donepezil 
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treatment of 431 community-dwelling people with mild to moderate Alzheimer's disease. The 
investigators found a median time to clinically evident decline of 6.9 months in the placebo 
group and 11.9 months in the donepezil group(50;60). 
Research has found no clinically important differences between people taking 
cholinesterase inhibitors and those taking placebo in the development of behavioral symptoms, 
although not all trials measure this important health outcome. No studies have reported results 
for more than 12 months of treatment, and studies rarely address other important health 
outcomes such as utilization of health care services, injuries, and caregiver burden. 
How Effective are Other Medications for People with Mild to Moderate Alzheimer's 
Disease? 
The evidence is weak that drugs other than cholinesterase inhibitors are beneficial in 
people with Alzheimer's disease. Several RCTs have examined the effects of ginkgo biloba on 
cognitive function in people with mild to moderate dementia. Two meta-analyses of these 
10 
studies, including one that examined only the four highest quality studies, found an approximate 
3% difference in cognitive scales between ginkgo biloba and placebo groups(61;62). A recent 
Cochrane review of 15 placebo-controlled studies found that selegiline, a selective monoamine 
oxidase inhibitor, produced a small improvement on cognitive testing, mood, and behavior but 
no improvement in global clinical ratings(63). The evidence that selegiline affects other health 
outcomes is limited. A 2-year RCT also examined the effect of vitamin E in people with 
moderate Alzheimer's disease(64). The investigators found that vitamin E had no effect on 
cognitjon but limited evidence that it delayed institutionalization. No other well-conducted 
RCTs have examined the effects of vitamin E. Two recent well-conducted RCTs examined 
estrogen therapy for women with mild to moderate dementia(65;66). After 15 months, the study 
found no difference between estrogen and placebo groups. 
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How Effective are Neuroleptics in Treating Behavioral Problems Associated with Mild To 
Moderate Dementia Syndrome? 
A potential benefit of early detection of dementia is that problem behaviors associated 
with psychotic symptoms could be recognized and treated with neuroleptics. Although RCTs 
have examined these agents in people with more severe dementia, no study has examined this 
treatment in patients with mild to moderate dementia who would be detected by screening. 
How Effective are Antidepressants in People with Mild to Moderate Dementia? 
Many people with mild to moderate dementia are depressed. Two RCTs provided 
evidence that antidepressants are effective for depressive symptoms among community-dwelling 
elderly persons with mild to moderate Alzheimer's disease. One RCT with a crossover design 
showed that 6 weeks of therapy with clomipramine (a tricyclic antidepressant) reduced 
depressive symptoms( 55); in a recent study, Lyketsos eta!. found that sertraline effectively 
treated depression in individuals with both Alzheimer's disease and major depression( 58). The 
evidence is limited concerning the effects of antidepressants on cognition; no high -quality trial 
has examined other important health outcomes such as functional status, health-related quality of 
life, or clinician global clinical impression of change. 
How Effective are Nonpharmacologic Interventions for People with Mild to Moderate 
Dementia? 
Nonpharmacologic interventions for dementia include behavioral training, caregiver 
education, and supportive services. Nonpharmacologic interventions may be directed at either 
patients or their caregivers. Numerous studies of patient-directed interventions have targeted 
patients with severe dementia; no studies have targeted people with mild to moderate dementia. 
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Several well-conducted RCTs(67-72) and 1 systematic review(73) have examined 
nonpharmacologic interventions directed at caregivers of people with mild to moderate dementia 
(Table 4). Caregiver interventions are complex and varied but usually include 1 or more of the 
following components: support groups, individual or family counseling, skills training, or 
education. Caregiver interventions were studied for benefit to patient health outcomes and for 
evidence of benefit to caregivers themselves. 
A systematic review found no significant differences in caregiver burden between 
intervention and control groups and concluded that little or no evidence exists that interventions 
to support caregivers of people with Alzheimer's disease yield quantifiable benefit(73). Two 
other RCTs had similar findings(67-69), while another 2 found modest benefits(71;74). The two 
positive studies involved multi-component interventions that reduced caregiver burden(67;69). 
One of these positive RCTs found that a multi-component caregiver intervention also 
improved the functional status of care recipients, although the magnitude of this improvement is 
unclear(71 ). Two other studies found that intensive, comprehensive caregiver interventions 
enabled caregivers to maintain the affected persons at home for a substantially longer period of 
time (between 11 and 19 months) than those who did not receive the intervention(75;76). 
Does Knowledge of a Dementia Diagnosis Improve Patient and Family Planning for 
Future Medical Care and Safety? 
Individuals identified with early dementia by screening may have the opportunity to 
discuss the nature of the syndrome, its prognosis, and future planning in regard to health care, 
safety, and fmances. They may be able to formulate advance directives, choose a person to 
exercise power of attorney for financial and personal care decisionmaking, consent to participate 
in research, and contemplate issues such as motor vehicle driving, self-neglect, financial 
victimization, and housing relocation. It may also permit earlier and more effective 
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administration of medication for co-existing conditions by improving medication adherence and 
avoiding drug interactions. No high-quality study has been done to verify, quantify, or refute 
these potential benefits. 
What are the Adverse Effects of Screening and Early Treatment of Dementia? 
The harms of dementia screening have not been systematically studied. Potential harms 
include risk of depression and anxiety, the time and cost of screening, and possible labeling 
effects. Relatively few physicians have received sufficient training in the diagnostic skills 
required to diagnose dementia and its causes. Patients and families may face long delays after a 
positive screen before they can obtain a reference standard diagnostic work-up. Once a 
diagnosis of dementia is given, the patient will be unlikely to qualify for long-term care 
insurance or acceptance into a continuous care retirement community. However, in surveys of 
elderly patients and caregivers of Alzheimer's patients, most participants wanted to be told the 
diagnosis of dementia(77;78). 
The harms of treatment apply primarily to drugs, both cholinesterase inhibitors and 
others. Common side effects experienced by people taking cholinesterase inhibitors are nausea, 
vomiting, weight loss, and diarrhea. 
In the trials of galantamine, the dropout rate attributable to adverse events in participants 
ranged from 2% to 15% more in the drug group than the placebo group. In the trials of 
rivastigmine, the adverse effect rate was from 5% to 20% higher. In trials of higher dose (10 
mg) donepezil, the adverse effect rate was about 8% higher. Tacrine has significant 
gastrointestinal and hepatic side effects. The odds ratio for dropout because of adverse events 
among people who took tacrine is 5.7 (95% confidence interval; 4.1 - 7.9.). In RCTs of other 
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drugs, dropout rates did not differ significantly between people who took gingko biloba, 
selegiline, or vitamin E and those who took placebo. 
Discussion 
The prevalence of dementia increases rapidly in the seventh and eighth decades of life; 
the condition affects 25% to 4 7% of people over age 85. Patients suffer from progressive 
cognitive and functional dependence, psychotic and depressive symptoms, and injuries. The 
burden of disease also extends to the caregivers, who have high rates of emotional and financial 
stress and depression. Among all primary care patients over age 65 who have dementia, one-half 
are undiagnosed. 
No randomized trial has evaluated the overall efficacy of dementia screening in primary 
care. The MMSE is the best-studied brief screening tool for dementia. A cutpoint of 24 to 26 
out of 30 points is usually accepted as a positive screen. At this cutpoint, the MMSE can identifY 
cases of dementia with a sensitivity of 70% to 86% and specificity of 77% to 82%. Among the 
problems with this test are that scores must be adjusted for educational attaimuent and that the 
specificity is low enough that many people who test positive do not have dementia. 
Cholinesterase inhibitor treatment of people clinically detected with mild to moderate 
Alzheimer's disease results in modest but consistent improvements in cognition and clinician 
global impression of change scores. Little evidence exists for the effectiveness of 
antihypertensives or aspirin for vascular dementia. 
Limited evidence indicates that intensive, multi-component interventions to support 
caregivers may delay nursing home placement for people with Alzheimer's disease, but they 
have demonstrated few direct benefits for either patient or caregiver. Further benefits of 
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screening, including individual and family planning and better decisions about health care 
interventions for other conditions, have not been studied. 
The harms of dementia screening have not been systematically studied. Potential harms 
include risk of depression and anxiety, the time and cost of screening, and possible labeling 
effects. 
Limitations of this Review 
First, we did not include studies of mild cognitive impairment (MCI), a newly recognized 
condition that progresses to dementia in approximately 15% of patients. Any screening program 
is likely to identifY many older patients with MCI, but its natural history and response to 
treatment remain uncertain(79;80). Second, we limited our search to English language articles 
and thus may have excluded studies from relevant non-English speaking populations. However, 
we believe that our review successfully captured all studies that met inclusion criteria. 
Future Research Needs 
Important gaps remain in the current research on screening and treatment of dementia. 
An RCT of screening for dementia in primary care with prospective evaluation of multiple health 
outcomes would provide the best evidence for or against dementia screening. Given the high 
prevalence of undiagnosed dementia among primary care patients over age 65 and the efficacy of 
cholinesterase inhibitor treatment for clinically treated mild to moderate Alzheimer's disease, a 
trial of screening is justifiable. Such a trial should also monitor costs and harms and include the 
effects of screening and treatment on cognition, function, health care utilization, health-related 
quality of life, and caregiver burden. 
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The MMSE has been criticized for limited specificity and the need to adjust scoring for 
age and educational attainment. Future research should examine other promising brief screening 
tools that may be less education-dependent, testing their positive and negative predictive value in 
primary care. Although caregiver burden, increased health care utilization, problem behaviors, 
psychiatric symptoms, and accidental injury are common in dementia, little work to date has 
dealt with treatments to reduce these important aspects of the syndrome. The design of 
nonpharmacologic interventions might be refmed to target specific outcomes, such as problem 
behaviors or effective advance plarming for health care decisions and safety. No RCT has yet 
evaluated the efficacy of nonpharmacologic interventions on behavioral symptoms in patients 
with screen-detected mild to moderate dementia who live at home; this may be another important 
direction for research. 
Future pharmacologic treatment trials should routinely measure outcomes in addition to 
cognition and global clinical impression of change scores, including functional status, problem 
behaviors, and caregiver burden. In addition, outcome measures should be reported in temporal 
units such as time to decline or survival analyses, to provide data on stabilization of the disease 
course. 
Dementia after age 65 is common and creates significant suffering for patients and family 
caregivers. Routine clinical visits to primary care providers leave most cases of dementia 
undiagnosed, but a brief clinical screening test can improve case detection. Strong evidence 
supports the use of cholinesterase inhibitors to slow modestly the rate of cognitive decline in 
people with clinically detected Alzheimer's disease. Their effectiveness in screening-detected 
Alzheimer's disease is less certain. Potential benefits of screening could increase with the 
discovery of more effective treatment for early, screening-detected Alzheimer's disease and 
vascular dementias. 
Manuscript for Review Purposes: Do Not Cite, Quote, Reproduce, or Distribute Without Pennission 
February 12, 2002 
.__ 
L 
f 
' 
Screening for Dementia 17 
Table 1. Key Issues, Inclusion Criteria, and Number of Articles Meeting Criteria 
Issue Inclusion Criteria 
Number of Systematic Reviews 
and Articles Meeting Criteria 
All 
Prevalence of 
undiagnosed dementia 
Accuracy of screening 
tools 
Treatment for vascular 
dementia 
Pharmacologic 
interventions 
Non pharmacologic 
interventions 
Interventions for 
planning 
Caregiver interventions 
Harms of screening 
Published between 1/1/94 and 11/5/01 
English language 
Human subjects, age 60+ 
MEDLINE, PsychiNFO, 
EMBASE, Cochrane Library 
Systematic reviews 
Cross-sectional prevalence 
Community or primary care setting 
Appropriate reference standard 
Systematic reviews; RCTs 
Prospective cohort 
Cross-sectional 
Community or primary care setting 
Appropriate reference standard 
Systematic reviews, RCTs 
Mild to moderate dementia 
Health outcomes 
Systematic reviews, RCTs 
Mild to moderate dementia 
Health outcomes 
Systematic reviews, RCTs 
Mild to moderate dementia 
Health outcomes 
Systematic reviews, RCTs 
Mild to moderate dementia 
Health outcomes 
Systematic reviews, RCTs 
Mild to moderate dementia 
Health outcomes 
Systematic reviews, RCTs 
Mild to moderate dementia 
Psychological or other health outcomes 
Studies- 4 
Systematic review - 1 
Studies- 11 
Systematic review - 1 
Study- 1 
Studies- 19 
0 
0 
Systematic review -1 
Studies- 5 
0 
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Table 2. Estimates of Undiagnosed Dementia in Primary Care Practices 
Study 
Olafsdottir et al., 
2000(21) 
Setting 
Primary health 
center, 
Sweden 
Age of Patient 
Population 
> 70 years 
Eefsting et al., 1996(26) Community and :0:65 years 
Valcour, et al., 
2000(22) 
Sternberg et al., 
2000(27) 
general practices, 
Netherlands 
General internal 
medicine clinic, 
Hawaii 
Community 
Canada 
:0:65 years 
:0:65 years 
*DSM-IIIR, Diagnostic and Statistical Manual ill, Revised. 
Reference 
Standard* 
OSM-IIIR 
OSM-111 
OSM-IIIR 
OSM-IIIR 
Prevalence of 
Missed Dementia in 
All Patients 
12.0% 
3.2% 
5.7% 
1.8% 
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Table 3. Efficacy of Cholinesterase Inhibitors in Alzheimer's Disease 
Drug 
(Number of Cognitive 
Trials) Function 
Tacrine + 
(2)(40;46) 
Donepezil + 
(5)(41 ;44;45;5 
0;52) 
Rivastigmine + 
(2)(42;43) 
Galantamine + 
(4)(47-49;51) 
Key: 
+: Statistically significant 
NS: No significant effect 
NT: Not tested 
Clinician-
assessed 
Global 
Function 
+ 
+ 
+ 
+ 
Physical 
Function: 
Activities of 
Daily Living Behavioral Quality of 
(ADLs) Symptoms Life 
NS NS NT 
+ NS NS 
+ NS NT 
+ NS NT 
19 
Caregiver 
Burden 
NT 
+ 
NT 
NT 
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Table 4. Summary of Efficacy of Caregiver Interventions 
Author, Year 
Mittleman et al., 
1996(70) 
Marriott et al., 
2000(72) 
McCurry et al., 
1998(71) 
Brodaty et al., 
1997(76) 
Hebert et al., 
1994(67;69) 
Hebert et al., 
1995(69) 
Key: 
+: Statistically significant 
NS: No significant effect 
NT: Not tested 
Patient Outcomes Caregiver Outcomes 
NT NT 
NS + 
NS + 
NT NT 
NS NS 
NS NS 
Time to Nursing Home 
Placement 
+ 
NT 
NT 
+ 
NS 
NS 
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